Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ATM W1058* ATM S1993fs |
Therapy | Fluorouracil + Leucovorin + Oxaliplatin |
Indication/Tumor Type | gastroesophageal adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM W1058* ATM S1993fs | gastroesophageal adenocarcinoma | predicted - sensitive | Fluorouracil + Leucovorin + Oxaliplatin | Case Reports/Case Series | Actionable | In a retrospective analysis, treatment with the combination of Adrucil (fluorouracil), Wellcovorin (leucovorin), and Eloxatin (oxaliplatin) resulted in a partial response and a progression-free survival of 7.2 months in a patient with gastroesophageal adenocarcinoma harboring ATM W1058* and S1993fs (PMID: 37129948). | 37129948 |
PubMed Id | Reference Title | Details |
---|---|---|
(37129948) | BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP Inhibitors. | Full reference... |